Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com Research for Life
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com

Solidarity with scientists from Ukraine

GSH supports initiative #ScienceForUkraine for scientists from Ukraine by offering positions for scientists (undergrad, masters, PhDs, postdoctoral fellows, and associates). Read more ->

New insights in rectal carcinoma therapy

Research team from GSH, KGU & FCI discovered new resistance mechanism in rectal cancer therapy in which inflammatory connective tissue cells decrease response to radiochemotherapy. Read more ->

Diversity at the research institute

Georg-Speyer-Haus is part of Germany’s largest diversity network and is expressly committed to diversity in the work environment. With the Diversity Charter, GSH implements a variety of concepts and measures along all diversity dimensions as part of sustainable diversity management. Read more ->

Page 1 of 4.

1 2 3 4

Solidarity with scientists from Ukraine

#ScienceForUkraine – GSH supports initiative for scientists from Ukraine | Frankfurt am Main, March 08, 2022 – The Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy would be glad to host students as well as researchers (internships, bachelor and master theses, PhD, postdoctoral fellows, and associates) in fields of Life and Natural Sciences. We can… [mehr]

Hessischer Rundfunk visits on World Cancer Day

HR spotlights tumor research at Georg-Speyer-Haus on World Cancer Day | February 4 is World Cancer Day. To mark the occasion, the Hessischer Rundfunk took a closer look at Georg-Speyer-Haus. Why does radiation therapy work for one group of colorectal cancer patients and not for another? In fundamental research on tumor biology at GSH, researchers… [mehr]

New insights in rectal carcinoma therapy

Inflammatory connective tissue cells decrease response to radiochemotherapy | Frankfurt am Main, February 03, 2022 – Within the framework of the LOEWE Centre Frankfurt Cancer Institute (FCI), the group of Prof. Dr. Florian Greten from Georg-Speyer-Haus in cooperation with Prof. Dr. Claus Rödel and Prof. Dr. Dr. Emmanouil Fokas from the Department of Radiotherapy and… [mehr]

Diversity at research institute

Appreciation and esteem in their entire scope | Frankfurt am Main, July 2021 – The private foundation Chemotherapeutic Research Institute Georg-Speyer-Haus signs the Diversity Charter and visibly commits to an appreciative and bias-free working environment. With thus GSH sends a clear signal for diversity and tolerance in professional world and expresses their appreciation for all… [mehr]

Tumor-associated macrophages in brain metastases

Tumor-associated macrophages as therapeutic targets in brain metastases Frankfurt am Main, 10/19/2021 – The Max-Eder Junior Group led by Dr. Lisa Sevenich (Georg-Speyer-Haus) demonstrated in collaboration with researchers and clinicians at the University of Lausanne and the Institute of Neurology (Edinger Institute, University Hospital Frankfurt), that TAM-targeted therapies by colony stimulating factor 1 receptor (CSF1R)… [mehr]

ERC Advanced Grant 2021 goes to Prof. Dr. Greten

Great Award for Director of the Georg-Speyer-Haus Frankfurt am Main, April 22, 2021 – The European Research Council (ERC) is funding a project by Prof. Dr. Florian R. Greten with a prestigious Advanced Grant. Prof. Greten is director of the Georg-Speyer-Haus (GSH), Institute for Tumor Biology and Experimental Therapy, and speaker of the LOEWE -… [mehr]

1st certificate for GSH HR strategy

GSH receives audit berufundfamilie certificate For the first time, Georg-Speyer-Haus received the audit berufundfamilie certificate for the strategic design of its family- and life-phase-conscious personnel policy. The certificate, that is considered a label of quality for a company compatibility policy, is awarded by the board of trustees of berufundfamilie Service GmbH under the German Federal… [mehr]

Dr. Medyouf participates in EU ITN INTERCEPT-MDS

Dr. Medyouf participates in the European Innovative Training Network INTERCEPT-MDS focusing on the shared training and research in Myeloid Diseases.   Dr. Medyouf’s team will participate in the European Innovative Training Network (ITN) INTERCEPT-MDS, a Marie Skłodowska Curie Action, funded by the European Commission under H2020 framework programme, and coordinated by Dr. Marcus Buschbeck at… [mehr]

New EU research consortium with participation of GSH

GSH generates an extensive pharmacological drug library with other institutions and pharmaceutical companies | The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years,… [mehr]

Page 1 of 4.

1 2 3 4